-
Frailty Assessments Indicate Severe AE Probability in Prostate Cancer
28 Apr 2025 21:07 GMT
… prostate cancer may have less tolerability for treatment with upfront docetaxel, … prostate cancer who were treated with androgen deprivation therapy (ADT) plus upfront docetaxel … treated with upfront docetaxel or darolutamide plus docetaxel: a multicenter …
-
Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer.
28 Apr 2025 10:35 GMT
… biomarker in metastatic castration-resistant prostate cancer (mCRPC), as novel studies suggest … men with biochemical recurrence of prostate cancer.
A biobank prospectively collated at … .039). Among men treated with docetaxel, a %fPSA ≥15% was associated …
-
Expert Panel Addresses 5 Areas of Need in Metastatic Prostate Cancer
23 Apr 2025 16:20 GMT
… recurrent and advanced prostate cancer: consensus recommendations from the US Prostate Cancer Conference 2024 … therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1 …
-
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer - Beyond the Abstract
22 Apr 2025 23:57 GMT
… with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus … high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall … and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE …
-
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial.
21 Apr 2025 08:34 GMT
… metastatic hormone-sensitive prostate cancer receiving androgen deprivation therapy ± docetaxel (ADT ± D).
In … treatment tolerability in men with prostate cancer.
European urology oncology. 2025 Apr …
-
The Potential of Combination Therapy With Radiopharmaceuticals in Prostate Cancer
18 Apr 2025 20:40 GMT
… therapy with radiopharmaceuticals for prostate cancer treatment.
Combining radiopharmaceuticals with … for metastatic castration-resistant prostate cancer with bone metastases, alpha … with other therapies like docetaxel and immune checkpoint inhibitors …
-
PSMA-Targeted Antibodies for Prostate Cancer Radioligand Therapy "Presentation" - Scott Tagawa
18 Apr 2025 01:48 GMT
Read the Full Video Transcript
Scott Tagawa: All right. Thanks for the invitation. I'm going to shift gears a little bit. Still PSMA, but I'm going to talk about antibodies. I'm going to take a minute to tell you—I don't have an outline, so …
-
Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting (2)
17 Apr 2025 17:48 GMT
… hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel and for … in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Insights from … Patients with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): North American (NAm …
-
Reimagining PSMA Radioligand Therapy for Castration-Sensitive Prostate Cancer "Presentation" - Michael Morris
17 Apr 2025 01:25 GMT
Read the Full Video Transcript
Michael Morris: All right, I'm going to talk about moving into castration‑sensitive disease. There aren't that many studies in castration‑sensitive disease, so this is a design‑and‑thought discussion rather than a …
-
Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting
16 Apr 2025 12:28 GMT
… Hormone-Sensitive Prostate Cancer (mHSPC): … Castration-Resistant Prostate Cancer (nmCRPC): … prostate cancer (nmCRPC)
Metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel … Hormone-Sensitive Prostate Cancer
Prostate cancer is the …
About
© 1995-2025